Having lived with Crohn’s since 2002, I’ve learned to read the weekly IBD research landscape with a particular lens: what actually matters for those of us managing this disease day to day, and what’s still too early to change how we think about our care. This week brought a mix of preclinical findings, new research tools, and clinical guidance updates — none earth-shattering, but several worth understanding.

The standout piece for me was the Northwestern spatial transcriptomics work, which represents the kind of basic science that might inform treatment development years down the line. The black licorice research caught attention in popular media, but it’s early preclinical work that doesn’t change anything about how I manage my Crohn’s today. A new colon-on-a-chip model offers researchers better tools, and updated ACG guidelines reflect current clinical practice rather than new developments.

Spatial mapping of IBD tissue reveals cellular interactions

This is preclinical research published in Nature Communications by Northwestern Medicine scientists. The team developed what they call a “spatial transcriptomics atlas” — essentially a detailed map of how different cell types interact in the gastrointestinal tract of people with IBD.

The researchers analyzed tissue samples to understand which cells are talking to which other cells, and where these conversations happen in the gut. They found specific patterns of cellular communication that appear to drive inflammation and tissue damage in IBD. The work identifies particular cell types and signaling pathways that might be targets for future drug development.

What this means for me right now: nothing changes in how I manage my Crohn’s. This is foundational research that helps scientists understand the disease better, but it’s years away from translating into new treatments I could access.

The main limitation is that this is descriptive research — it shows us what’s happening at the cellular level, but doesn’t yet prove which of these interactions are causes versus effects of inflammation. The next step is figuring out which of these cellular conversations are actually driving disease progression.

Source: Northwestern Medicine News Center

Black licorice compound shows anti-inflammatory effects in lab studies

This is preclinical research examining glycyrrhizin, a compound extracted from black licorice root. Researchers found that this substance reduced inflammation and appeared to protect intestinal tissue from damage in laboratory models of IBD.

The studies were conducted in cell cultures and animal models, not humans. The researchers observed that glycyrrhizin seemed to interfere with inflammatory pathways and reduced markers of intestinal damage. The compound has been used in traditional medicine, but this represents more systematic laboratory investigation of its effects on IBD-like inflammation.

What this means for me right now: absolutely nothing. This is early laboratory work that’s nowhere near human clinical trials, let alone proving that eating black licorice would help my Crohn’s.

The limitation is that this is animal and cell culture research. Many compounds that show promise in these early models fail when tested in humans. There’s also no dosing information, safety data, or evidence that the amounts of glycyrrhizin you’d get from actual licorice would be therapeutic.

Source: NDTV Health

New lab model mimics IBD progression and sex differences

This is preclinical research published in Nature Biomedical Engineering describing an improved “colon-on-a-chip” device that better mimics human IBD. The researchers created lab models that can simulate disease progression, the development of cancer, and differences between male and female responses to inflammation.

The device includes human colon cells and can replicate the mechanical movements of the intestine. The researchers found that adding movement made inflammation worse, and that chips made with cells from women showed stronger inflammatory responses when exposed to pregnancy-related hormones. They could also model how chronic inflammation might lead to cancer development.

What this means for me right now: this is a research tool that might help scientists develop better treatments in the future, but it doesn’t change my current care.

The limitation is that this is still a laboratory model, not actual human tissue. While it’s more sophisticated than previous lab models, there’s always a gap between what happens in engineered devices and what happens in our actual guts.

Source: Nature Biomedical Engineering

Updated ACG guidelines for Crohn’s disease management

The American College of Gastroenterology released updated clinical practice guidelines for managing Crohn’s disease. These guidelines represent current best practices based on available evidence, not new research findings.

The updated recommendations cover standard topics: when to use different medications, how to monitor treatment response, surgical considerations, and management of complications. The guidelines reflect the current standard of care that most gastroenterologists already follow, incorporating biologics as first-line therapy for moderate to severe disease.

What this means for me right now: if my gastroenterologist is following evidence-based practice, I’m probably already receiving care that aligns with these guidelines.

The limitation is that clinical guidelines always lag behind the most recent research — they represent consensus about treatments that have been available for several years, not cutting-edge approaches that might be emerging.

Source: Gastroenterology & Endoscopy News

Looking across this week’s research, I’m struck by how much of the meaningful work happens in laboratories and research centers, building the foundation for treatments that might emerge years from now. The Northwestern spatial transcriptomics work and the improved colon-on-a-chip model are examples of the unglamorous but essential science that eventually leads to new therapies. Meanwhile, the updated clinical guidelines remind me that the treatments we have today — the biologics I’ve been on for years — represent the culmination of similar basic research that happened decades ago. Progress in IBD research is measured in years and decades, not weeks.